Researchers at MIT’s CSAIL and biotech firm Recursion have released Boltz‑2, an open-source AI model that can predict molecular binding affinity and structure up to 1,000× faster than traditional physics-based methods. This capability has the potential to dramatically accelerate virtual screening—a core part of drug discovery—by profoundly reducing time and cost.
Boltz‑2 not only speeds up screenings but also integrates predictions of protein structure and dynamics in one go—offering deeper insights for pharmaceutical R&D . The open-source nature of this model encourages global collaboration and could be particularly valuable to Indian biotech firms and academic institutions working in drug discovery. It’s a prime example of how AI is bridging the gap between computational modeling and real-world medical applications.
